Rapid Micro Biosystems, Inc.
NASDAQ:RPIDMedical - Devices
+$0.03 today
- Market cap
- $50.31M
- Beta
- 1.46
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.10
Volume 0.17M
Average 0.18M
RPID Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Rapid Micro Biosystems, Inc.NASDAQ: RPID
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$3.23M, compared with $3M a year earlier. Trailing-twelve-month accounts receivables was -$1.84M.
Context
- Accounts receivables amounted to 13.1% of revenue in FY2025, up 6.0 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$3.23M or moves back toward the trailing-twelve-month quarterly average of -$461K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 4.39M USD
- Year-over-year change
- +320.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.39M | +320.8% |
| FY2024 | 2024-12-31 | (1.99M) | -1119.0% |
| FY2023 | 2023-12-31 | (163K) | +55.2% |
| FY2022 | 2022-12-31 | (364K) | -2041.2% |
| FY2021 | 2021-12-31 | (17K) | — |
Accounts Receivables vs competitors
How RPID compares with its peers on the latest reported figures
- RPID's LTM Mar 2026 accounts receivables of $1.84M is the 4th largest of the 9 companies compared; the peer median is $254K.
- Its year-over-year change of -561.0% is the 8th highest of 9, against a peer median of +46.3%.
- Accounts receivables amounts to 5.4% of revenue for RPID, versus a peer median of 4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.32M | -36.0% | +8.9% | 3.1% | |
| LTM Mar 2026 | $3.09M | +162.7% | — | 4.3% | |
| LTM Mar 2026 | $2.39M | +188.7% | — | 4.1% | |
| LTM Mar 2026 | $1.84M | -561.0% | — | 5.4% | |
| LTM Mar 2026 | $1.31M | -404.9% | — | 2.3% | |
| LTM Mar 2026 | $1.12M | +128.6% | +72.7% | — | |
| LTM Mar 2026 | $631K | +5158.3% | — | 12.3% | |
| LTM Mar 2026 | $522K | -769.2% | — | — | |
| LTM Mar 2026 | $14K | -80.8% | — | 24.6% | |
| Peer median (excluding RPID) | $254K | +46.3% | +40.8% | 4.2% | |
Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.52M) | (60.81M) | (52.47M) | (46.89M) | (47.12M) |
| Depreciation & Amortization | 1.53M | 2.84M | 3.11M | 3.36M | 3.25M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.84M | 4.02M | 4.75M | 3.87M | 4.03M |
| Change in Working Capital | (8M) | (5.33M) | 555K | (4.77M) | 6.06M |
| Accounts Receivables | (17K) | (364K) | (163K) | (1.99M) | 4.39M |
| Inventory | (6.77M) | (5.84M) | 1.19M | (335K) | 1.47M |
| Accounts Payables | (524K) | 1.48M | (3.46M) | 562K | 1.6M |
| Other Working Capital | (691K) | (602K) | 2.98M | (3.01M) | (1.39M) |
| Other Non-Cash Items | 23.19M | 728K | (1.02M) | 271K | 2.71M |
| Operating Cash Flow | (54.96M) | (58.55M) | (45.08M) | (44.15M) | (31.06M) |
| Capital Expenditures | (3.22M) | (6.74M) | (1.85M) | (1.37M) | (850K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (25.09M) | (179.23M) | (62.49M) | (35.04M) | (27.08M) |
| Sales of Investments | 15M | 92.5M | 106.49M | 73.06M | 42.26M |
| Other Investing Activities | 20K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (13.29M) | (93.47M) | 42.15M | 36.66M | 14.33M |
| Debt Repayment | (26.17M) | (33K) | (37K) | (35K) | 19.09M |
| Common Stock Issued | 164.11M | 0 | 0 | 238K | 1.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (940K) | 726K | 186K | 0 | (419K) |
| Financing Cash Flow | 216.75M | 693K | 149K | 203K | 19.77M |
| Effect of Forex Changes | 0 | 0 | 0 | (81K) | 0 |
| Net Change in Cash | 148.49M | (151.32M) | (2.78M) | (7.37M) | 3.04M |
| Free Cash Flow | (58.18M) | (65.29M) | (46.93M) | (45.52M) | (31.91M) |
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.